A comprehensive view of Teva Pharmaceutical Industries Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Vanda Pharmaceuticals' attempts to uphold patents for circadian rhythm drug Hetlioz denied by the US Supreme Court; the decision follows an earlier legal loss against generic drug manufacturers Teva and Apotex & an FDA rejection of Hetlioz usage expansion
Published: April 23, 2024 by FiercePharma
INTERNATIONAL PATENT: TAKEDA PHARMACEUTICAL COMPANY LIMITED, CEPHALON LLC, TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, ARANA THERAPEUTICS, INC., POGUE, SARAH FILES APPLICATION FOR "CD38-BINDING FUSION PROTEIN COMBINATION THERAPY"
Published: April 10, 2024 by U.S. Fed News
World Intellectual Property Organization Receives Teva Pharmaceuticals Int GmbH and Teva Pharma's Patent Application for Solid State Forms of Nirogacestat Salts
Published: April 10, 2024 by Pharmaceutical Patent News
Teva Pharmaceuticals partners with mAbxience to develop and commercialize oncology biosimilar in EU and US; mAbxience to handle development and production, while Teva will manage regulatory and commercialization activities
Published: April 05, 2024 by PharmaShots
UroGen Pharma files lawsuit against Teva Pharmaceuticals in Delaware District Court for alleged patent infringement related to UroGen's cancer drug, JELMYTO, following Teva's attempt to seek FDA approval for a generic version of the drug
Published: April 04, 2024 by Associated Press

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count